LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

5.74 -1.88

Rezumat

Modificarea prețului

24h

Curent

Minim

5.72

Maxim

5.79

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+30.66% upside

Dividende

By Dow Jones

Următoarele câștiguri

16 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

50M

288M

Deschiderea anterioară

7.62

Închiderea anterioară

5.74

Sentimentul știrilor

By Acuity

43%

57%

103 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 feb. 2026, 23:21 UTC

Achiziții, Fuziuni, Preluări

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb. 2026, 23:06 UTC

Câștiguri

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb. 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb. 2026, 20:48 UTC

Câștiguri

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb. 2026, 20:47 UTC

Câștiguri

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb. 2026, 20:46 UTC

Câștiguri

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb. 2026, 20:45 UTC

Câștiguri

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb. 2026, 20:43 UTC

Câștiguri

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb. 2026, 20:41 UTC

Câștiguri

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb. 2026, 20:39 UTC

Câștiguri

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

30.66% sus

Prognoză pe 12 luni

Medie 7.5 USD  30.66%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

103 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat